#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Cytokine release syndrome Short stature Hyperinsulinaemic hypoglycaemia Congenital ectodermal dysplasia Endocrine ophthalmopathy Infective uveitis Pulmonary hypertension Glioblastoma Loss of consciousness Metastases to peritoneum HER2 gene amplification Sickle cell anaemia Ovarian cancer stage III Transitional cell carcinoma Glomerulonephritis chronic More trials…

    Learn about Rare Diseases

    Langerhans cell sarcoma – Treatment Glycogen storage disease type I Gaucher’s disease type I – Trials in Disease Angelman’s syndrome – Trials in Disease Anaplastic thyroid cancer – Trials in Disease Tuberous sclerosis complex – Diagnostics Cystic fibrosis – Trials in Disease Ocular melanoma – Trials in Disease Short-bowel syndrome – Trials in Disease Cystic fibrosis lung – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Gallium (68Ga) Gozetotide Anitocabtagene Autoleucel Pal1-15 Acetate VENT-03 Gfh925 Amifostine Thiol Etrumadenant Interleukin-1 Dexamethasone Metformin Hydrochloride Enasidenib Mesilate Tecovirimat Lenvatinib Quinidine Sulfate Spironolactone Pritelivir Adrenaline Acid Tartrate Bp Ziltivekimab Betula Alba Pollen Extract Asfotase Alfa More therapies…

    Learn about Your Condition

    Chorea Primary myelofibrosis Bone marrow disorder Mantle cell lymphoma recurrent Gastric cancer recurrent Colorectal cancer stage II Agitation postoperative Tendon disorder Essential thrombocythaemia Fragile X syndrome Pneumonia Peritoneal dialysis Malignant fibrous histiocytoma Catatonia Keratosis follicular More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Uncategorized

  • Study of Lower Dose Olaparib Combined with Cobicistat to Improve Treatment Tolerance in Cancer Patients

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Neoplasm malignant
    Investigated Drugs:
    • Cobicistat
    The Netherlands

  • Imaging Study with 89Zr-Bevacizumab for Predicting Treatment Effects in Patients with NF2-Related Schwannomatosis

    Recruiting

    2 1 1
    Investigated Diseases:
    • Neurofibromatosis
    Investigated Drugs:
    • Bevacizumab Zirconium Zr-89
    The Netherlands

  • Study on Alisertib with Hormone Therapy for Patients with HR+, HER2- Recurrent or Metastatic Breast Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Alisertib Sodium
    • Anastrozole
    • Exemestane
    Portugal Spain

  • Evaluating SGM-101 (fluorochrome-labeled antibody) in patients with locally advanced or recurrent rectal cancer undergoing surgery

    Recruiting

    2 1 1
    Investigated Diseases:
    • Rectal cancer
    Investigated Drugs:
    • Chimeric Monoclonal Antibody Against Carcinoembryonic Antigen Conjugated To Fluorochrome Bm-104
    The Netherlands

  • Study on Early Oxybutynin Treatment for Boys with Posterior Urethral Valves

    Recruiting

    2 1 1
    Investigated Diseases:
    • Urethral valves
    Investigated Drugs:
    • Oxybutynin
    France

  • Study on the Effect of Recombinant Human Interferon Gamma 1b for Patients with Post-Aggressive Immunosuppression in Intensive Care

    Recruiting

    3 1 1
    Investigated Diseases:
    • Immunosuppression
    Investigated Drugs:
    • Recombinant Human Interferon Gamma 1B
    • Sodium Chloride
    France
Previous Page
1 … 386 387 388 389 390 … 1,651
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!